Tripep initiates preparations for a phase I/II study of ChronVac-C® vaccine

Tripep initiates preparations for a phase I/II study of ChronVac-C® vaccine

Following the advice from the Swedish Medical Products Agency (MPA) Tripep has
started the preparations for a phase I/II study of Tripep's ChronVac-C® vaccine
delivered by Inovio's Medpulser® DDS.  An application for approval of a phase
I/II study will be submitted to the MPA as soon as possible to enable the study
to start during 2007 and be completed during 2008. 

”The advice from the MPA means that Tripep in a shorter time frame and at a
lower cost can reach ”proof of concept” in man for our combination of
ChronVac-C®, delivered by Inovios Medpulser® DDS”, says Tripep's CEO Jan
Nilsson.

ChronVac-C® is a therapeutic vaccine, i.e. it is given to individuals already
infected by the hepatitis C virus with the purpose of halting the infection by
boosting the immune response.

In December 2006 Tripep filed an application with the Swedish Medical Products
Agency for a phase I clinical study with ChronVac-C® with the intent to commence
the phase I study in the spring of 2007. Typically, phase I studies are
performed on healthy volunteers with the primary goal of ensuring safety of the
drug, i.e. that it does not cause significant adverse effects.  Following
discussions with the Swedish Medical Products Agency during the spring 2007,
Tripep has decided to start the clinical development program of ChronVac-C® with
a combined phase I/II study in subjects previously infected with HCV. Phase I/II
studies are typically performed in patients who carry the disease which makes it
possible to evaluate potential side effects, as well as, efficacy of the drug.

Tripep's ChronVac-C® vaccine, administered with Inovio's Medpulser® DDS, has in
an animal model proven to selectively wipe out hepatitis C virus protein
producing liver cells. The total market for therapies against hepatitis C
infections is estimated to over 2 billion dollars and is expected to grow to
more than 8 billion dollars by 2015 according to Datamonitor. 


For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .